FDA has issued a new reminder to compounders regarding the legal limits on compounding GLP-1-related drugs, including products involving semaglutide and tirzepatide, as the national supply of these medications begins to stabilize.

The April 1, 2026 statement is significant for both traditional compounding pharmacies and outsourcing facilities. It signals FDA's continued focus on compounded products that may be considered “essentially copies” of commercially available drugs.

Why FDA's Statement Matters

During periods of drug shortage, compounders may have more flexibility to prepare certain medications. But as supply improves, that flexibility narrows. FDA is reminding compounders that compounded drugs must meet the statutory conditions under section 503A or section 503B of the Federal Food, Drug, and Cosmetic Act to qualify for exemptions from certain federal requirements.

For pharmacies and outsourcing facilities involved in GLP-1 compounding, this means now is the time to revisit product offerings, prescription practices, documentation, and compliance procedures.

What FDA Said About 503A Compounding Pharmacies

Under section 503A, compounded drugs must generally be prepared for an individual patient based on receipt of a prescription. FDA also emphasized that compounders may not compound, regularly or in inordinate amounts, products that are essentially copies of commercially available drug products.

According to FDA, a compounded drug may be considered essentially a copy if it has the same active pharmaceutical ingredient as a commercially available drug, in the same, similar, or easily substitutable strength, and can be used by the same route of administration.

There is an important exception: if a prescriber determines and documents that the compounded product contains a change that produces a significant difference for the identified individual patient, the product may avoid being treated as an essentially copied product.

Combination Products May Still Be Treated as Copies

FDA also addressed compounded products that combine multiple active ingredients. The agency explained that adding another API does not necessarily prevent a product from being considered essentially a copy.

For example, FDA stated that a compounded injectable product combining semaglutide with another API, such as vitamin B12, may be treated as essentially a copy of commercially available products if the ingredients are used in the same, similar, or easily substitutable strengths and by the same route of administration.

This clarification is important because some compounders have marketed GLP-1 combination products as distinct from commercially available medications. FDA's statement indicates that the agency may look beyond the presence of an added ingredient and evaluate whether the compounded product is functionally substitutable for available commercial products.

FDA's Four-Prescription Enforcement Policy

FDA also noted that, at this time, it does not intend to take action against a compounder for compounding a product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.

This is not a broad safe harbor for GLP-1 compounding. Rather, it is a limited enforcement policy tied to prescription volume and the specific circumstances described by FDA.

What FDA Said About 503B Outsourcing Facilities

FDA's statement is also important for outsourcing facilities operating under section 503B.

Outsourcing facilities are restricted from compounding drugs using bulk drug substances unless the substance appears on FDA's 503B bulks list or the drug compounded from the substance appears on FDA's drug shortage list at the time of compounding, distribution, and dispensing.

FDA specifically stated that semaglutide and tirzepatide do not currently appear on the 503B bulks list or FDA's drug shortage list.

That statement has immediate compliance implications for outsourcing facilities that have been compounding GLP-1 products using bulk API.

Compliance Considerations for Compounders

In light of FDA's statement, compounders should consider reviewing:

• Whether each compounded GLP-1 product is supported by an individual patient prescription;
• Whether the product could be considered essentially a copy of a commercially available drug;
• Whether any claimed difference is documented by the prescriber as producing a significant difference for the identified patient;
• Monthly prescription volumes for any potentially copied product;
• Whether the relevant API appears on FDA's 503B bulks list;
• Whether the drug appears on FDA's drug shortage list at the time of compounding, distribution, and dispensing; and
• Marketing, intake, and prescribing workflows that may suggest routine production of commercially available substitutes.

The Bottom Line

FDA's April 1, 2026 statement reinforces that GLP-1 compounding remains subject to strict federal limits. As supply stabilizes, compounders should not assume that practices permitted or tolerated during shortage conditions will remain acceptable.

For 503A pharmacies, the focus should be on patient-specific prescriptions, avoiding routine copies of commercially available products, and documenting any significant clinical differences. For 503B outsourcing facilities, the key question is whether the applicable API is permitted under the 503B bulks framework or whether the drug is on FDA's shortage list at the relevant time.

Compounders involved with semaglutide, tirzepatide, or GLP-1 combination products should promptly evaluate their current practices and documentation to reduce regulatory risk.

This article is for informational purposes only and does not constitute legal advice. Regulatory developments are ongoing, and the information presented here reflects the state of affairs as of the publication date. Providers and pharmacies should consult qualified legal counsel before making compliance decisions based on anticipated regulatory changes.